

# CRITICAL REVIEWS™ IN IMMUNOLOGY

AUTHOR INDEX, VOLUME 38, 2018

---

## Page Range of Issues

Issue 1: 1–78; Issue 2: 79–158; Issue 3: 159–252; Issue 4: 253–342; Issue 5: 343–431; Issue 6: 433–524

---

Aboulnasr, F., 491	Huber, S., 415	Rezende, R.M., 207
Badley, A.D., 491	Hutton, A.J., 367	Rhoads, J.P., 333
Bcdkc, T., 415	Kabayashi, T., 105	Rip, J., 17
Bialoszewska, A., 479	Kaplan, H.J., 233	Shao, H., 233
Born, W.K., 233	Kawai, T., 279	Sima, C., 343
Bos, N.A., 145	Kimura, T., 403	Sok, S.P.M., 279
Boto, P., 63	Kondo, M., 471	Soukou, S., 415
Bourque, J., 379	Krocse, F.G.M., 145	Staples, K.J., 367
Brockmann, I., 415	Kumanogoh, A., 403	Sun, D., 233
Buart, S., 505	Lancioni, C.L., 1	Szatmari, I., 63
Chen, W., 245	Liang, D., 233	Tanaka, Y., 471
Chirino, L., 105	Liu, Y., 79	Teets, A., 159
Chouaib, S., 505	Ma, C., 79	Terry, S., 505
Corneth, O.B.J., 17	Major, A.S., 333	Tran, F.L., 159
Cremer, I., 263	Malejczyk, J., 479	Uebelhoer, L.S., 1
Csuth, T.I., 63	Metcalf, J.P., 303	Uzunhan, Y., 263
de Roquetaillade, C., 433	Miyagawa, I., 471	Van Der Ploeg, F.K., 17
Deshmukh, R., 159	Mo, P., 245	Van Dyke, T.E., 343
Dominguez, D., 453	Momercet, G., 433	Vcnct, F., 433
Flavell, R.A., 415	Nagoor, N.H., 279	Venkatesh, G.H., 505
Francis, A., 505	Nakayamada, S., 471	Vicillard, V., 263
Freen-van Heeren, J.J., 131	Nawafleh, H.H., 505	Warner, J.A., 367
Freund-Brown, J., 105	Nicolet, B.P., 131	Weiner, H.L., 207
Gagliani, N., 415	O'Brien, R.L., 233	Wolkers, M.C., 131
Gayed, C., 263	Okada, M., 403	Yu, C., 245
Gossez, M., 433	Ori, D., 279	Zaarour, R.F., 505
Hawiger, D., 379	Paranjape, G., 491	Zeinclabdm, N.A., 505
Hendricks, J., 145	Paster, B., 343	Zhang, B., 453
Hendriks, R.W., 17	Patel, V.I., 303	Zhang, N., 79
Hervier, B., 263	Pham, L., 159	Zhang, Y., 453
Hochmuth, L., 159	Prasad, P., 505	Zhao, B., 253

# CRITICAL REVIEWS™ IN IMMUNOLOGY

SUBJECT INDEX, VOLUME 38, 2018

## Page Range of Issues

Issue 1: 1–78; Issue 2: 79–158; Issue 3: 159–252; Issue 4: 253–342; Issue 5: 343–431; Issue 6: 433–524

- adenosine deaminase (ADA), 233  
adenosine receptors, 233  
anti-arr-t-synthetase  
autoantibody, 263  
antibody, 333  
antigen presentation, 367  
anti-synthetase syndrome, 263  
antitumor immunity, 453  
antitumor response, 505  
atherosclerosis, 333  
autoimmunity, 17, 233, 263, 279  
avclumab, 159  
B cell receptor, 17  
B cells, 479  
bacteria, 367  
bacterial clearance, 245  
bacterial infection, 245  
B-cell, 333  
bone resorption, 253  
Bruton's tyrosine kinase, 17  
cancer, 105, 479, 505  
CD4, 79  
CD4+ T-cells, 403  
CD8, 79  
CD8+ T cells, 453  
cell differentiation, 63  
cell-mediated cytotoxicity, 479  
cellular signaling, 17  
cGAS-STING, 279  
checkpoint inhibitors, 159  
chondrocytes, 479  
cytokines, 131  
cytotoxic T cells, 63  
cytotoxic T lymphocyte, 491  
dendritic cell, 379  
dendritic cells, 63, 453, 479  
DNA damage, 505  
DNA sensors, 279  
dysbiosis, 343  
effector function, 131  
effector T cell, 379  
experimental autoimmunity  
uveitis, 233  
fibroblast, 367  
Flow-FISH, 131  
Foxp3, 233  
growth factor, 471  
gut mucosa, 207  
host defense, 245  
human mesenchymal stem cells, 471  
human, 367  
hypoxia, 505  
IBD, 415  
IL-15, 79  
IL-33, 453  
IL-7, 433  
immunity, 403  
immunoglobulin heavy (IGH) chain genes, 145  
immunometabolism, 343  
immunoregulation, 379  
immunotherapy, 105, 433  
infant, 1  
infection, 79, 105  
inflammasome, 279  
inflammation resolution, 343  
inflammation, 253  
inflammatory myopathy, 263  
innate and adaptive immune cells, 207  
innate immunity, 279, 303  
insulin-like growth factor, 471  
interferon gamma, 1  
Lamtor1, 403  
lung, 367  
lymphocyte exhaustion, 433  
macrophage, 333  
macrophages, 403, 479  
marginal zone (MZ), 145  
memory B cells, 145  
memory, 79  
Merkel cell carcinoma, 159  
monocytes, 303  
natural killer (NK) cells, 105  
natural killer cell, 491  
neonate, 1  
NK cells, 479  
NTHi, 367  
oral tolerance, 207  
osteoblasts, 479  
osteoclasts, 253  
oxLDL, 333  
PD-L1, 159  
phagocytes, 303  
plasma dendritic cell, 491  
pulmonary fibrosis, 263  
rat, 145  
regulatory T cell, 379, 233  
regulatory T cells, 403, 471  
respiratory system, 303  
RNA, 131  
RUNX3, 63  
sepsis, 433  
septic shock, 433  
signal transduction, 105  
small-molecule inhibitor, 17  
spleen, 145  
ST2, 453  
steroid receptor coactivator-3, 245  
T cell differentiation, 379  
T cell, 1, 379, 333  
T cells, 131, 367, 479  
T-cell activation, 491  
T-cell therapy, 415  
TGF- $\beta$ , 79  
Th1 immunity, 1  
Th17, 233  
TNF, 253  
Toll-like receptor, 279  
TRAIL agonist, 491  
TRAIL antagonist, 491  
TRAIL receptor, 491  
transcription factors, 63  
transcriptional profiling, 303  
Treg cells, 415  
tumor microenvironment, 505  
tumor necrosis factor, 491  
type 1 regulatory T cells, 415  
urothelial cell carcinoma, 159  
uveitis, 233  
 $\gamma\delta$  T-cell, 233  
 $\Omega$ -3 polyunsaturated fatty acids, 343

## **CRITICAL REVIEWS™ IN IMMUNOLOGY**

### **REVIEWERS - 2018**

The Editor gratefully acknowledges the cooperation and participation of the reviewers for the year 2018.

Bai, X.-F.  
Beaulieu, A.  
Bergsbaken, T.  
Boer, M.  
Bonavida, B.  
Borir, R.  
Caspi, R.  
Charles, J.  
Cichocki, F.  
Freire, M.  
Geginat, J.  
Genco, R.  
Hirata, S.  
Huang, W.

Jacubzick, C.  
Kang, I.  
Kyaw, T.  
Li, X.  
Menczes, G.  
Moudgil, K.  
Nitschke, L.  
Nojima, S.  
Peromet, E.  
Pillai, S.  
Puttabyatappa, M.  
Qin, L.  
Rohr, J.  
Satoh, S.

Scotton, C.  
Selva, A.  
Simandi, Z.  
Takami, M.  
Takeduchi, O.  
Taniuchi, I.  
Vanck, O.  
Wakim, I.  
Want, T.  
Williams, A.  
Zenewicz, I.  
Zenke, M.

